The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) reached all time high today, Nov, 16 and still has $86.60 target or 47.00% above today’s $58.91 share price. This indicates more upside for the $1.70 billion company. This technical setup was reported by Barchart.com. If the $86.60 PT is reached, the company will be worth $799.00 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 62,257 shares traded hands. Five Prime Therapeutics Inc (NASDAQ:FPRX) has risen 23.61% since April 14, 2016 and is uptrending. It has outperformed by 18.92% the S&P500.
Five Prime Therapeutics Inc (NASDAQ:FPRX) Ratings Coverage
Out of 5 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Five Prime Therapeutics has been the topic of 9 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Credit Suisse maintained it with “Outperform” rating and $52 target price in Friday, March 11 report. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) earned “Outperform” rating by Oppenheimer on Monday, October 19. The rating was upgraded by Zacks to “Sell” on Friday, August 21. The rating was upgraded by Zacks to “Sell” on Tuesday, August 11. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) earned “Outperform” rating by Credit Suisse on Thursday, January 21. The rating was initiated by Citigroup on Friday, July 31 with “Buy”. Wells Fargo maintained the stock with “Outperform” rating in Friday, December 4 report. The stock has “Buy” rating given by Citigroup on Tuesday, October 25. BMO Capital Markets initiated Five Prime Therapeutics Inc (NASDAQ:FPRX) rating on Tuesday, April 12. BMO Capital Markets has “Market Perform” rating and $50 price target.
According to Zacks Investment Research, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California.”
Insitutional Activity: The institutional sentiment increased to 2.29 in Q2 2016. Its up 1.04, from 1.25 in 2016Q1. The ratio increased, as 15 funds sold all Five Prime Therapeutics Inc shares owned while 34 reduced positions. 47 funds bought stakes while 65 increased positions. They now own 24.20 million shares or 3.63% more from 23.35 million shares in 2016Q1.
Moreover, Prudential Financial Incorporated has 0% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 20,492 shares. Shell Asset last reported 0.02% of its portfolio in the stock. Grp Inc One Trading Lp has 0% invested in the company for 351 shares. Jpmorgan Chase And accumulated 80,629 shares or 0% of the stock. The New York-based Clinton Gp Inc has invested 0.05% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Jefferies Gp Ltd last reported 14,100 shares in the company. Qs Investors Ltd Liability Corporation owns 38,800 shares or 0.01% of their US portfolio. The Pennsylvania-based Vanguard Grp Incorporated has invested 0% in Five Prime Therapeutics Inc (NASDAQ:FPRX). Envestnet Asset Mngmt has 0% invested in the company for 1,047 shares. New York State Common Retirement Fund reported 31,987 shares or 0% of all its holdings. Moreover, Oppenheimer And has 0.01% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 11,625 shares. Assetmark Inc has 18 shares for 0% of their US portfolio. Rock Springs Capital Mngmt L P accumulated 153,000 shares or 0.47% of the stock. Teachers Advsrs Inc has 232,862 shares for 0.02% of their US portfolio. Fernwood Investment Mgmt Limited Liability Corporation has 6,650 shares for 0.27% of their US portfolio.
Insider Transactions: Since July 27, 2016, the stock had 0 insider purchases, and 6 selling transactions for $1.15 million net activity. $603,653 worth of Five Prime Therapeutics Inc (NASDAQ:FPRX) was sold by Jensen Peder. On Monday, August 1 the insider RINGO WILLIAM R sold $25,385.
Another recent and important Five Prime Therapeutics Inc (NASDAQ:FPRX) news was published by Benzinga.com which published an article titled: “Citi Launches Positive Coverage On Five Prime Therapeutics” on October 25, 2016.
FPRX Company Profile
Five Prime Therapeutics, Inc. (Five Prime), incorporated on December 20, 2001, is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The Firm has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Firm seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.